Participant recruitment and informed consent were performed under Institutional Review Board (IRB)-approved protocols at the US National Institutes of Health (NIH) and University of Washington. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood by density gradient centrifugation. PBMC were incubated with Fcγ-receptor-blocking reagent for 10 minutes and stained with LIVE/DEAD Aqua stain, CD3-APC-H7 (BD Biosciences; Cat# 641406), CD4-BV785 (BioLegend; Cat# 317442), CD8-PacBlue (Invitrogen; Cat# MHCD0828), CD14-BV650 (BioLegend; Cat# 301836), CD16-PerCP/Cy5.5 (BioLegend; Cat# 302028), CD19-BV605 (BD Biosciences; Cat# 562653), CD20-BV570 (BioLegend; Cat# 302332), CD27-Alx700 (BioLegend; Cat# 302814), CD32-PE (BioLegend; Cat# 303206); CD45RO-ECD (Beckman Coulter; Cat# IM2712U), CD123-PE/Cy5 (BD Biosciences; Cat# 551065), and TCRγδ-APC (BD Biosciences; Cat# 555718). CD4+ T cells were isolated by fluorescence-activated cell sorting (FACS) on a FACSAria (Becton Dickinson) using previously described protocols32 (link).